Is Medtronic's Dividend Safe?

For not just years but decades, Medtronic (NYSE: MDT) has proven to be a reliable dividend growth stock to own. The medical device maker has been increasing its payout regularly, and with a yield of more than 3%, it pays more than twice what the S&P 500 averages (1.3%).

But these days, the stock's payout ratio is high, and investors may think twice about how safe the dividend is. A long streak, after all, is no guarantee that future payouts will be secure. Let's take a closer look at whether Medtronic's dividend is safe and if you can comfortably rely on its payout for the foreseeable future.

Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. See the 10 stocks »

Medtronic's payout ratio is well over 80%

A stock's payout ratio is a key metric that dividend investors will focus on when assessing if the payout is sustainable. The higher the payout ratio is, the less room the company has to cover the dividend should its earnings deteriorate. That doesn't automatically mean that if it gets to over 100%, a dividend cut is coming. But it can be a warning sign, nonetheless.

Over the trailing 12 months, Medtronic's diluted earnings per share has totaled $3.27. And when you consider the company's annual dividend totals $2.80, that means the healthcare company is paying out approximately 86% of its earnings as dividends.

While Medtronic has regularly posted profits, the danger is that it may not be strong enough to leave room for the company to invest in its operations and continue growing its dividend, as Medtronic has been doing for years. The company has increased its dividend for an impressive 47 consecutive years, but it is clear from the chart below that the rate of those increases has indeed been slowing down.

MDT Dividend data by YCharts

What does Medtronic's free cash flow say?

Another way investors can evaluate the safety of a dividend is by reviewing a company's free cash flow. This can sometimes be a better indicator of how much room there is to support the dividend simply because free cash flow tells investors how much cash the company is generating after factoring in capital expenditures. Thus, it represents the cash that is available to either pay out as dividends or invest back into the business.

Over the past four quarters, Medtronic's free cash flow has totaled $5.5 billion. By comparison, the company has paid out $3.6 billion in dividends during that stretch. But in the past two quarters, Medtronic's free cash has been lower than its dividend payments. Cash flow can fluctuate and depend on the timing of receivables and the payment of payables, but the recent trend of not having sufficient free cash to cover dividend payments is a concern that investors should keep a watch for in future periods.

Should you invest in Medtronic for its dividend?

Medtronic's dividend appears to be safe for now. However, between its elevated payout ratio and free cash flow not being higher than its dividend in recent quarters, there are definitely signs here that the rate of dividend increases may continue to tighten up in future years. Another issue is that the dividend could hinder Medtronic's ability to aggressively grow its business, and that could be a problem for long-term investors.

In the past five years, Medtronic's stock has fallen by around 30%. While that dividend income may be appealing, investors may be questioning what it's all for if the business isn't generating a high level of growth (currently, its growth rate is around 5%) and producing strong returns. That could, however, change as investors start to potentially pay more toward value stocks -- Medtronic is trading at just 14 times next year's estimated earnings.

Overall, Medtronic's dividend is safe for now, but there may be better income-generating investments out there to choose from that can offer a better mix of growth and dividends.

Don’t miss this second chance at a potentially lucrative opportunity

Ever feel like you missed the boat in buying the most successful stocks? Then you’ll want to hear this.

On rare occasions, our expert team of analysts issues a “Double Down” stock recommendation for companies that they think are about to pop. If you’re worried you’ve already missed your chance to invest, now is the best time to buy before it’s too late. And the numbers speak for themselves:

• Nvidia: if you invested $1,000 when we doubled down in 2009, you’d have $363,385!*
• Apple: if you invested $1,000 when we doubled down in 2008, you’d have $45,870!*
• Netflix: if you invested $1,000 when we doubled down in 2004, you’d have $474,140!*

Right now, we’re issuing “Double Down” alerts for three incredible companies, and there may not be another chance like this anytime soon.

See 3 “Double Down” stocks »

*Stock Advisor returns as of January 6, 2025

David Jagielski has no position in any of the stocks mentioned. The Motley Fool recommends Medtronic and recommends the following options: long January 2026 $75 calls on Medtronic and short January 2026 $85 calls on Medtronic. The Motley Fool has a disclosure policy.